Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270965
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
530±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270965
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-2-oxopiperidin-1-yl]-N-methylacetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL500475
Type:
Small organic molecule
Emp. Form.:
C72H102N18O16S2
Mol. Mass.:
1539.821
SMILES:
CC(C)C[C@H](N(C)C(=O)CN1CCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:102.107,83.86,18.26,62.65,14.14,98.104,wD:4.4,51.61,47.49,43.45,75.79,29.37,(27.77,-6.06,;27.77,-4.53,;29.1,-3.76,;26.45,-3.76,;26.45,-2.22,;25.24,-1.34,;25.35,.19,;23.88,-2.07,;23.83,-3.6,;22.58,-1.25,;21.22,-1.97,;21.17,-3.51,;19.81,-4.23,;18.51,-3.42,;18.56,-1.88,;17.26,-1.07,;15.9,-1.79,;15.91,-3.34,;14.62,-.93,;14.62,.63,;15.95,1.4,;17.28,.62,;18.61,1.39,;18.61,2.93,;17.27,3.7,;15.94,2.93,;13.39,-1.81,;12.04,-1.09,;12.04,.45,;10.76,-1.95,;10.76,-3.5,;12.1,-4.27,;13.56,-3.78,;14.47,-5.02,;13.58,-6.27,;12.11,-5.81,;9.37,-1.07,;8.01,-1.79,;8.02,-3.34,;6.74,-.93,;5.52,-1.81,;4.17,-1.09,;4.17,.45,;2.89,-1.95,;1.68,-1.07,;.34,-1.85,;.35,-3.39,;-1,-1.08,;-2.33,-1.87,;-3.69,-1.14,;-3.69,.41,;-4.98,-2.01,;-4.98,-3.56,;-3.64,-4.35,;-2.3,-3.57,;-.96,-4.35,;-.96,-5.89,;-2.3,-6.66,;-3.64,-5.89,;-6.19,-1.12,;-7.56,-1.84,;-7.55,-3.4,;-8.84,-.97,;-10.06,-1.87,;-8.84,.58,;-7.5,1.35,;-7.5,2.9,;-6.17,3.63,;-6.13,5.17,;-4.77,5.9,;-7.45,5.98,;-1.01,.47,;-2.56,.45,;-1.02,2.02,;.54,.47,;2.89,-3.5,;1.56,-4.27,;4.22,-4.27,;19.91,-1.15,;19.96,.39,;27.71,-1.37,;27.72,.17,;29.07,-2.09,;30.28,-1.21,;30.28,.33,;31.35,1.43,;32.84,1.04,;33.92,2.14,;33.51,3.62,;34.58,4.72,;32.01,4,;30.94,2.91,;31.54,-2.07,;31.55,-3.61,;32.9,-1.35,;33.12,.17,;34.63,.43,;35.35,-.92,;34.29,-2.03,;34.55,-3.55,;33.37,-4.53,;36,-4.08,;37.21,-3.21,;37.21,-1.65,;38.54,-.89,;38.48,-4.06,;39.84,-3.33,;38.49,-5.59,)|
Structure:
Search PDB for entries with ligand similarity: